Annovis Bio Patents New Composition for Buntanetap

MALVERN, Pa., June 26, 2024 – Annovis Bio Inc. (NYSE: ANVS), a company at the forefront of developing therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), has announced a significant milestone. The company has filed a new composition of matter patent with the U.S. Patent and Trademark Office. This patent pertains to novel solid forms of their drug, buntanetap, building on a provisional patent filed in June 2023. 

These new crystalline forms of buntanetap present notable benefits over less structured forms, including improved solubility and stability. The most stable crystalline form of the drug (CAS# 3032752-92-1) has been selected as the new lead compound for further animal studies and for the development of a manufacturing process. These bridge studies have been submitted to the FDA and will undergo discussion in July. The ultimate aim is to continue the development of the drug and file a New Drug Application (NDA) using this new crystal form.

Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, expressed her enthusiasm, stating, “The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company. This achievement will allow us not only to continue advancing our pipeline but also to enhance the drug's properties, ultimately providing greater benefits to our patients.”

The composition of matter patent provides protection for the new crystalline form of buntanetap and its applications for a period of 20 years. This type of patent is crucial for pharmaceutical companies as it offers sufficient time to develop and bring a new drug to market.

Buntanetap, formerly known as Posiphen or ANVS401, is designed to tackle neurodegeneration by inhibiting the formation of several neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This inhibition leads to improvements in synaptic transmission and axonal transport and reduces neuroinflammation. Disruptions in these pathways are known to cause nerve cell degeneration and death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in diseases such as Alzheimer’s and Parkinson’s, aiming to restore brain function and enhance the quality of life for patients.

Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is committed to addressing neurodegenerative diseases through innovative approaches. The company's strategy focuses on targeting multiple neurotoxic proteins to restore brain function and improve patient quality of life. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!